β2AR是恶性黑色素瘤预后潜在的生物标志物  

β2AR is a Potential Biomarker for Prognosis of Malignant Melanoma

作　　者：姚翠英[1] 陈芳[1] Yao Cuiying;Chen Fang(Tianyou Hospital Affiliated to Wuhan University of Science and Technology,Wuhan,430064)

机构地区：[1]武汉科技大学附属天佑医院

出　　处：《基因组学与应用生物学》2019年第10期4800-4805,共6页Genomics and Applied Biology

基　　金：武汉科技大学科技基金项目(2016CFB171)资助

摘　　要：β2-肾上腺素能受体(β2AR)可在恶性黑色素瘤中表达,然而,β2AR在恶性黑色素瘤中的表达模式及其预后意义尚不明确。本研究选择62例恶性黑色素瘤患者进行研究,选择30例黑素细胞痣组织标本作为对照。采用实时荧光定量PCR、蛋白质印迹分析和免疫组织化学染色检测恶性黑色素瘤和黑素细胞痣组织中的β2AR表达情况,并分析了β2AR表达与CD34和Ki-67表达的相关性。RT-PCR和Western blotting研究显示,与黑素细胞痣组织相比,恶性黑色素瘤组织中的β2AR、CD34和Ki-67的mRNA和蛋白表达水平均显著升高(p<0.05)。免疫组化染色结果显示,TNM分期为Ⅲ~Ⅳ的恶性黑色素瘤患者的β2AR高表达率显著高于Ⅰ~Ⅱ期患者(p=0.005)。肿瘤大小>20 mm2的患者的β2AR高表达率显著高于肿瘤大小≤20 mm2的患者(p=0.025)。Ki-67和CD34高表达的患者的β2AR高表达率显著升高(p<0.05)。Spearman相关分析显示,β2AR、Ki-67和CD34的表达显著正相关(p<0.05)。β2AR高表达组患者的死亡和复发率显著高于β2AR低表达组(p<0.05)。β2AR的高表达是预测皮肤恶性黑色素瘤患者预后不良的潜在生物标志物。选择性抑制β2AR的分子靶向药物可能是恶性黑色素瘤治疗的新策略。β2-adrenergic receptor(β2AR)can be expressed in malignant melanoma.However,the expression pattern ofβ2AR in malignant melanoma and its prognostic significance are still unclear.This study selected 62 patients with malignant melanoma for study.In addition,30 melanocytic nevus tissue specimens were selected as controls.Real-time quantitative PCR,Western blotting analysis and immunohistochemical staining were used to detect the expression ofβ2AR in malignant melanoma and melanocytic nevus tissues,and the correlation betweenβ2AR expression and CD34 and Ki-67 expression was analyzed.RT-PCR and Western blotting studies showed that the mRNA and protein expression levels ofβ2AR,CD34 and Ki-67 in malignant melanoma tissue were significantly higher than those in melanocytic nevus tissue(p<0.05).Immunohistochemical staining showed that the high expression rate ofβ2AR in patients with malignant melanoma with TNM stageⅢ~Ⅳwas significantly higher than that in patients with stageⅠ~Ⅱ(p=0.005).The high expression rate ofβ2AR in patients with tumor size>20 mm^2 was significantly higher than in patients with tumor size≤20 mm^2(p=0.025).The high expression rate ofβ2AR was significantly increased in patients with high Ki-67 and CD34 expression(p<0.05).Spearman correlation analysis showed thatβ2AR was significantly positively correlated with the expression of Ki-67 and CD34(p<0.05).The mortality and recurrence rate of patients with highβ2AR expression were significantly higher than those with low expression ofβ2AR(p<0.05).High expression ofβ2AR is a potential biomarker for predicting poor prognosis in patients with cutaneous malignant melanoma.Molecular targeting drugs that selectively inhibitβ2AR may be a new strategy for the treatment of malignant melanoma.

关 键 词：恶性黑色素瘤 Β2-肾上腺素能受体 TNM分期 肿瘤大小 预后因素 生物标志物 

分 类 号：R73[医药卫生—肿瘤]